We are utilizing our proprietary FORCE™ platform to overcome the current limitations of muscle tissue delivery with modern oligonucleotide therapeutic candidates. We are developing a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). We have assembled a world-class team united by a commitment to fulfill our mission.
Location: United States, Massachusetts, Waltham
Employees: 51-200
Total raised: $465M
Founded date: 2017
Investors 6
| Date | Name | Website |
| 19.11.2020 | Logos Capi... | logoscapit... |
| - | Vida Ventu... | vidaventur... |
| 18.05.2023 | MPM Capita... | mpmcapital... |
| - | Forbion | forbion.co... |
| - | RA Capital... | racap.com |
| - | Atlas Vent... | atlasventu... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 04.01.2024 | - | $300M | - |
| 11.08.2020 | - | $115M | - |
| 05.04.2019 | Series A | $50M | - |
Mentions in press and media 25
| Date | Title | Description | Source |
| 05.03.2024 | Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 ... | - | globenewsw... |
| 04.01.2024 | Dyne Therapeutics Announces Pricing of $300 Million Public O... | WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-s... | forbion.co... |
| 04.01.2024 | Dyne Therapeutics Announces Pricing of $300 Million Public O... | - | globenewsw... |
| 03.11.2022 | Dyne Therapeutics Reports Third Quarter 2022 Financial Resul... | /EIN News/ -- - DYNE-101 ACHIEVE and DYNE-251 DELIVER Clinical Trials Underway with Data Anticipated... | einpresswi... |
| 18.01.2022 | Dyne Therapeutics Announces FDA Clinical Hold on IND Applica... | WALTHAM, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle di... | marketscre... |
| 02.12.2021 | Dyne Therapeutics Announces Submission of IND Application to... | - DYNE-251, Dyne’s First DMD Program, is Being Developed for Patients with Mutations Amenable to Ski... | marketscre... |
| 03.04.2021 | Dyne Therapeutics : Reports Fourth Quarter and Full Year 202... | - Preclinical Data Further Validate FORCE™ Platform; Driving Toward IND Submissions for DM1, DMD and... | marketscre... |
| 04.03.2021 | DYNE THERAPEUTICS, INC. Dyne Therapeutics : Reports Fourth ... | - Preclinical Data Further Validate FORCE™ Platform; Driving Toward IND Submissions for DM1, DMD and... | marketscre... |
| 11.08.2020 | DYNE THERAPEUTICS ANNOUNCES $115 MILLION FINANCING TO ADVANC... | - | mpmcapital... |
| 10.08.2020 | Dyne Therapeutics Raises $115M in Equity Financing | Dyne Therapeutics, a Waltham, Mass.-based biotechnology company focused on developing life-transform... | finsmes.co... |
Show more